Status:
COMPLETED
Study of the Nevisense Device to Assess Atypical Skin Lesions
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Nevus
Multiple Nevi
Eligibility:
All Genders
30+ years
Brief Summary
The purpose of this study is to find out whether the Nevisense device can provide useful information about atypical moles to complement the usual assessments done during routine screening for melanoma...
Eligibility Criteria
Inclusion
- Adult patients (\> 30 years of age) at the time of the initial study visit.
- Patients displaying a phenotype that consists of ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) \> 5 mm in diameter. These patients have "atypical mole syndrome", which is a high-risk nevus phenotype and the target patient population in this study.
- Patients with at least three clinically stable nevi between 5 and 20 mm in diameter.
- Patients (or LAR) who are able to provide informed consent.
- Patients with previous total body photography images taken at least 3 years prior
Exclusion
- Patients without at least three clinically stable nevi between 5 and 20 mm in diameter.
- Patients with any electronic implantable devices.
- Patients who are pregnant (verbally confirmed with the participant).
Key Trial Info
Start Date :
January 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 18 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04705168
Start Date
January 8 2021
End Date
November 18 2025
Last Update
November 20 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Basking Ridge (Consent only)
Basking Ridge, New Jersey, United States, 07920
2
Memorial Sloan Kettering Westchester (Consent only)
Harrison, New York, United States, 10604
3
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065